Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 29, 2016

Study Completion Date

November 28, 2017

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Denosumab

Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.

DRUG

Zoledronic acid

Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.

DRUG

Placebo to Denosumab

Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.

DRUG

Standard Chemotherapy

Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.

DRUG

Placebo to Zoledronic Acid

Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.

Trial Locations (74)

2076

Research Site, Wahroonga

2217

Research Site, Kogarah

3011

Research Site, Footscray

3050

Research Site, Parkville

3690

Research Site, Wodonga

5000

Research Site, Adelaide

10043

Research Site, Orbassano (TO)

11522

Research Site, Athens

11733

Research Site, East Setauket

12462

Research Site, Athens

14076

Research Site, Caen

14165

Research Site, Berlin

20900

Research Site, Monza (MB)

21047

Research Site, Saronno VA

21079

Research Site, Dijon

21157

Research Site, Westminster

22927

Research Site, Großhansdorf

26504

Research Site, Pátrai

27100

Research Site, Pavia

27157

Research Site, Winston-Salem

27710

Research Site, Durham

28602

Research Site, Hickory

33604

Research Site, Pessac

37044

Research Site, Tours

37203

Research Site, Nashville

44202

Research Site, Nantes

45267

Research Site, Cincinnati

48202

Research Site, Detroit

51056

Research Site, Reims

51109

Research Site, Köln-Merheim

54622

Research Site, Thessaloniki

57010

Research Site, Thessaloniki

58501

Research Site, Bismarck

71110

Research Site, Heraklion

71301

Research Site, Alexandria

75020

Research Site, Paris

75475

Research Site, Paris

75674

Research Site, Paris

85338

Research Site, Goodyear

89081

Research Site, Ulm

90024

Research Site, Los Angeles

90048

Research Site, Los Angeles

90813

Research Site, Long Beach

92801

Research Site, Anaheim

06030-1628

Research Site, Farmington

04412

Research Site, Brewer

02719

Research Site, Fairhaven

T6G 1Z2

Research Site, Edmonton

E2L 4L2

Research Site, Saint John

P3E 5J1

Research Site, Greater Sudbury

N2G 1G3

Research Site, Kitchener

M5G 2M9

Research Site, Toronto

M9N 1N8

Research Site, Toronto

H2W 1S6

Research Site, Montreal

430 12

Research Site, Chomutov

708 52

Research Site, Ostrava-Poruba

532 03

Research Site, Pardubice

180 81

Research Site, Prague

401 13

Research Site, Ústí nad Labem

02321

Research Site, Saint-Quentin

00128

Research Site, Roma

5223 GZ

Research Site, 's-Hertogenbosch

6815 AD

Research Site, Arnhem

3844 DG

Research Site, Harderwijk

5022 GC

Research Site, Tilburg

7207 AE

Research Site, Zutphen

BS2 8ED

Research Site, Bristol

EX2 5DW

Research Site, Exeter

G42 9LF

Research Site, Glasgow

GU2 7XX

Research Site, Guildford

SE1 9RT

Research Site, London

W6 8RF

Research Site, London

PL6 8DH

Research Site, Plymouth

PR2 9HT

Research Site, Preston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01951586 - Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter